Rippl Care
Series A in 2024
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.
RareCyte
Venture Round in 2024
RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.
Cadence Neuroscience
Venture Round in 2023
Cadence Neuroscience, Inc. is an early-stage company focused on developing innovative medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company is leveraging core technology developed at the Mayo Clinic, which is currently under clinical evaluation. Cadence's implantable devices are designed to detect specific brain signals and deliver tailored electrical stimulation to modify neural circuit activity. This approach aims to enhance seizure control and improve treatment methods, offering medical practitioners a customizable solution for managing neurological conditions.
Rippl Care
Seed Round in 2022
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.
Latchel, Inc. is a technology company that specializes in providing an online platform for maintenance coordination tailored for property managers and landlords. Founded in 2016 and located in Bellevue, Washington, Latchel's software allows property management companies to efficiently track maintenance requests, select vendors, and enhance tenant satisfaction. The platform facilitates communication between tenants and property managers through a mobile application, enabling residents to schedule maintenance and address tasks promptly. By streamlining operations, Latchel aims to improve net margins for property managers and elevate the overall quality of maintenance services offered to residents.
LogixBoard
Series B in 2022
Logixboard, Inc. is a Seattle-based company established in 2016 that specializes in developing a cloud platform specifically for freight forwarders. This platform enhances transparency and communication between logistics service providers and their customers. As a white-labeled customer experience software, Logixboard allows these providers to increase sales and improve customer retention by integrating seamlessly with their existing internal systems. The implementation of Logixboard's solution can be completed in less than three weeks with minimal effort from the logistics teams. Additionally, the platform offers real-time tracking and big data analytics, equipping the supply chain and logistics sector with the necessary tools to stay competitive amidst the ongoing digitization of the industry.
RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.
LogixBoard
Series A in 2021
Logixboard, Inc. is a Seattle-based company established in 2016 that specializes in developing a cloud platform specifically for freight forwarders. This platform enhances transparency and communication between logistics service providers and their customers. As a white-labeled customer experience software, Logixboard allows these providers to increase sales and improve customer retention by integrating seamlessly with their existing internal systems. The implementation of Logixboard's solution can be completed in less than three weeks with minimal effort from the logistics teams. Additionally, the platform offers real-time tracking and big data analytics, equipping the supply chain and logistics sector with the necessary tools to stay competitive amidst the ongoing digitization of the industry.
Sana Biotechnology
Series A in 2020
Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.
Avalyn Pharma
Series B in 2020
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.
LogixBoard
Seed Round in 2019
Logixboard, Inc. is a Seattle-based company established in 2016 that specializes in developing a cloud platform specifically for freight forwarders. This platform enhances transparency and communication between logistics service providers and their customers. As a white-labeled customer experience software, Logixboard allows these providers to increase sales and improve customer retention by integrating seamlessly with their existing internal systems. The implementation of Logixboard's solution can be completed in less than three weeks with minimal effort from the logistics teams. Additionally, the platform offers real-time tracking and big data analytics, equipping the supply chain and logistics sector with the necessary tools to stay competitive amidst the ongoing digitization of the industry.
RiskLens, Inc. specializes in cyber risk management software that enables organizations to quantify and manage cyber risk from a business perspective. The company's offerings include Cyber Risk Maturity, which assesses an organization's risk management capabilities and compliance with established frameworks; Cyber Risk Triage, a tool for prioritizing risk scenarios; and Cyber Risk Third-Party, which evaluates the risk management practices of external partners. Additionally, RiskLens provides Cyber Risk Quantification, a solution that estimates financial exposure to cyber events, as well as a standard value at risk model for both cyber and operational risks. The platform is designed for chief information risk officers and chief information security officers, assisting them in making informed decisions about cybersecurity investments and insurance policies. RiskLens serves a diverse range of sectors, including financial services, government, healthcare, education, and technology. Founded in 2011 and headquartered in Spokane, Washington, the company was previously known as CXOWare, Inc.
Sana Biotechnology
Seed Round in 2019
Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.
Sana Biotechnology
Seed Round in 2018
Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.
Avalyn Pharma
Venture Round in 2017
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.
VitalWare
Series A in 2015
VitalWare, LLC is a provider of revenue cycle software as a service (SaaS) solutions tailored for healthcare organizations. Founded in 2011 and based in Yakima, Washington, the company offers a comprehensive suite of tools designed to enhance the efficiency of healthcare documentation, coding, billing, and auditing processes. Its products include VitalCDM, which aids in charge management; VitalCDI, which enhances clinical documentation; and iDocuMint, a web-based tool that streamlines the documentation process. Additional offerings such as VitalIntegrity, VitalIntelligence, and VitalKnowledge support compliance with regulatory requirements and improve financial outcomes for healthcare providers. With a client base of over 590 healthcare institutions, VitalWare focuses on delivering solutions that provide visibility in Chargemaster management, charge capture, and regulatory compliance, ultimately helping organizations achieve better reimbursement and operational improvements.
FutureAdvisor
Series B in 2014
FutureAdvisor, founded in 2010 and based in Seattle, Washington, specializes in investment advisory services aimed at simplifying wealth management for clients. The company offers a platform that provides personalized, data-driven recommendations to optimize 401(k) plans and IRAs. Its services include financial projections and individualized diversification strategies to enhance investment portfolios. Recognizing the challenges many investors face, FutureAdvisor leverages the principles of index investing, which historically outperforms many actively managed funds, to guide clients in making informed decisions. By focusing on low-cost investment options, FutureAdvisor seeks to make effective wealth management accessible to a broader audience. In 2015, FutureAdvisor became a subsidiary of BlackRock, Inc., further strengthening its capabilities in the financial advisory sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.